Provectus Biopharms (PVCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Sales | 336 | 617 | 558 | 989 | 0 |
| Gross Profit | 336 | 617 | 558 | 989 | N/A |
| Operating Expenses | 5,631 | 5,150 | 3,459 | 4,417 | 4,672 |
| Operating Income | -5,295 | -4,532 | -2,901 | -3,428 | -4,672 |
| Interest Expense | 210 | 239 | 216 | 164 | 962 |
| Other Income | 0 | 9 | 16 | 37 | 95 |
| Pre-tax Income | -5,505 | -4,762 | -3,102 | -3,555 | -5,540 |
| Net Income Continuous | -5,505 | -4,762 | -3,102 | -3,555 | -5,540 |
| Minority Interests | -74 | -30 | N/A | N/A | N/A |
| Net Income | $-5,431 | $-4,733 | $-3,102 | $-3,555 | $-5,540 |
| EPS Basic Total Ops | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Basic Continuous Ops | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted Total Ops | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted Continuous Ops | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted Before Non-Recurring Items | -0.01 | -0.01 | -0.01 | N/A | N/A |
| EBITDA(a) | $-5,293 | $-4,525 | $-2,892 | $-3,417 | $-4,659 |